Compare TOWN & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TOWN | BLLN |
|---|---|---|
| Founded | 1998 | 2016 |
| Country | United States | United States |
| Employees | 1251 | 713 |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.5B |
| IPO Year | N/A | N/A |
| Metric | TOWN | BLLN |
|---|---|---|
| Price | $34.83 | $90.31 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $126.71 |
| AVG Volume (30 Days) | ★ 463.2K | 273.6K |
| Earning Date | 04-23-2026 | 03-04-2026 |
| Dividend Yield | ★ 3.17% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.63 | $45.96 |
| Revenue Next Year | $5.18 | $30.11 |
| P/E Ratio | $16.23 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.90 | $61.96 |
| 52 Week High | $37.86 | $138.70 |
| Indicator | TOWN | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 60.88 | 63.41 |
| Support Level | $34.69 | $88.00 |
| Resistance Level | $34.90 | $100.28 |
| Average True Range (ATR) | 0.59 | 5.86 |
| MACD | 0.25 | 2.34 |
| Stochastic Oscillator | 87.73 | 85.99 |
Towne Bank is a financial services company serving individuals, commercial enterprises and professionals, offering retail and commercial banking services in Virginia and North Carolina. The company has four reportable segments: Banking, which provides loan and deposit services, commercial mortgage brokerage, and investment and asset management services; Mortgage, which originates mortgage loans principally sold in the secondary market through purchase commitments from investors; Resort Vacation Management, which provides residential resort property management services; and Insurance, which provides property, casualty, life and health insurance solutions for businesses, individuals and community organizations through a variety of carriers.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.